There are at least FIVE things that impact how you respond to taking Semaglutide or Wegovy and Ozempic - as they are commonly known, for weight loss. Today I look into what they are. The ultimate issue I discuss is why does a a 100 kilo woman and a 300 kilo man routinely both get perscribed the same dosing schedule and can we do it better?

Contact

[email protected]

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECT of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. I encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.

Links to Documents mentioned in the Podcast

Australian Public Assessment Report Wegovy

European Medicines Agency Assessment Report Semaglutide

European Medicines Agency Assessment Report Wegovy

FDA Centre for Drug Evaluation and Research Clinical Review

FDA Centre for Drug Evaluation and Research Summary Wegovy

Why did Novo Nordisk get banned from the British Pharmaceutical Society for two years - what kind of outrageous behaviour triggers a response like that? I look into the class action lawsuits in the USA and talk about previous lawsuits that Novo Nordisk have settled. I also look into the millions of dollars that Novo Nordisk have spent on health care professionals world wide. What are the implications of that?

Contact

[email protected]

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECT of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. I encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.

Links to Documents mentioned in the Podcast

Guardian Article non disclosure

Increase in Payments equals increase in writing perscriptions

Increase in Payments equals increase in scripts Australia

British Pharmaceutical ban Novo Nordisk

Reuters article on USA payments by Novo Nordisk

Class Action Lawsuit USA

Medicines Australia link to look up doctor payments

JAMA article on vision loss

Royal College UK handing back funds article

This week I take a comprehensive look at all of the Side Effects - or as the clinical trial data likes to call them - Adverse Events. I look at what is the percentage of people that suffer from them and find out that it is the Gastric Side Effects that affect the majority of the population who are using Ozempic or Wegovy for weight loss. I also talk to fascinating and vivacious Shauna about both of her experiences on taking Ozempic for weight loss and what is the social stigma of making those choices.

Contact

[email protected]

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECT of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. I encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.

Links to Documents mentioned in the Podcast

Complete Novo Nordisk Clinical Trial Step 5 trial (100+ pages)

Wegovy Side Effects as per website

Clinical Trials.gov Step 5 trial data

I look into why Wegovy possibly got approved at a 2.4mg dosage. What were the percentage of side effects found in clinical trials and why the hell did our Government Regulators say "yes". We take a look at the speed of weight loss and why it matters in Advertising. Plus what GLP1's have in common with the smash hit show "The Biggest Loser". I push for more personalised dosages of semaglutide and we look at the battle of Big Pharma for the consumer dollar and how it all comes down to being the ultimate biggest loser.... because who the hell remembers the runner up?

Contact

[email protected]

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECT of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. I encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.

LINKS TO DOCUMENTS MENTIONED

Wegovy Dosage Trial

Ozempic Dosage Trial

2019 Review of GLP1 by 20 Scientists

STEP 1 Clinical Trial

STEP 2 Clinical Trial

STEP 3 Clinical Trial

STEP 4 Clinical Trial

STEP 5 Clinical Trial

Adolescent STEP Clinical Trial

Tirzepeptide vs Semaglutide

https://pubmed.ncbi.nlm.nih.gov/37344384/

Lower Cagrisema Media Notice

Blue Health Intelligence Survey

So much controversy is packed into this relatively short Investigating Ozempic Podcast.

How did the weekly administered Wegovy (semaglutide) drug get approved for the higher dosage of 2.4mg after doing a controversial dosage trial that conducted testing daily rather than weekly. Why did the Government Regulators approve this dosage after expressing some concerns and why did World Scientists publish questions over using higher dosages of Semaglutide (GLP1's) for weight loss? Is it all to do with Gastric side effects?

So many questions for the Global Blockbuster Drug Wegovy and so much to think about over the Christmas break.

Contact

[email protected]

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECT of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. I encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.

LINKS TO DOCUMENTS MENTIONED

Wegovy Dosage Trial

Ozempic Dosage Trial

2019 Review of GLP1 by 20 Scientists

European Medicines Agency Assessment Report of Wegovy

Novo Nordisk Tosemaglutide daily testing trial in Germany

FDA partially redacted notes on Semaglutide

In 2017 two respected Danish Scientists claimed that higher dosages of the GLP1 Semaglutide, which had been planned as a treatment for Obesity, were not supported by the Clinical trials. I look at the timing of this article and their controversial statement. I search for the missing Phase II Ozempic Clinical trials and take a look at the Phase III Ozempic Trials on Diabetics and question the small amount of weight loss found alongside the large number of side effects. I also chat to Kevin about his surprising Mounjaro weight loss journey.

Contact

[email protected]

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECT of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. I encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.

LINKS TO DOCUMENTS MENTIONED

Danish female Scientist Deadline show video

https://www.dr.dk/nyheder/indland/laegeformand-deadline-ringede-og-morgenen-efter-landede-der-et-tilbud-fra-novo

Annals of Translational Medicine Article

annals: https://atm.amegroups.org/article/view/17434/html

Ozempic Clinical Trials:

SUSTAIN 1

https://clinicaltrials.gov/study/NCT02054897?tab=results

SUSTAIN 2 clinical trial

https://clinicaltrials.gov/study/NCT01930188?term=%20NCT01930188&rank=1

SUSTAIN 3 clinical trial

https://clinicaltrials.gov/study/NCT01885208?term=NCT01885208&rank=1&tab=results

SUSTAIN 4 clinical trial

https://clinicaltrials.gov/study/NCT02128932?term=NCT02128932&rank=1

SUSTAIN 5 clinical trial

https://clinicaltrials.gov/study/NCT02305381?term=NCT02305381&rank=1

SUSTAIN 6 clinical trial - Heart Study

https://clinicaltrials.gov/study/NCT01720446?term=NCT01720446&rank=1

This week we look backwards in time in order to move forwards. We check out the first GLP1 drugs and take a longer look at Liraglutide which is a GLP1 found in Victoza (diabetes) and Saxenda (weightloss). We also chat to Lorrie and talk in depth about her journey on Saxenda and why she ended up choosing it over Ozempic.

Lorrie faced many challenges on her journey and I highlight three of the main ones that usually anyone faces when first going on a GLP1 medicine for weight loss. We also take a look at the lawsuits currently underway in the USA over Saxenda and how Novo Nordisk has had to pay out millions of dollars to settle, plus we take a look at the numerous lawsuits claiming gastrointestinal issues and is there any link between them and the clinical trials?

Links to Documents:

European Medicines Agency Report on Liraglutide

Australian Public Assessment Report on Liraglutide

SCALE Liragutide Clinical Study 3.0mg dosage

Korean University Study

Contact

[email protected]

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECTS of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. We encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.

This week I look at the previous and present CEO's of Novo Nordisk and examine their different passion projects and attitudes towards weight loss drugs. I ask the question why didn't the previous CEO push the button on the Wegovy clinical trials after many of the Ozempic clinical trials had been completed? What made him hesitate... and more importantly why did the new CEO make initiating those trials one of his first big decisions?

I look at how CEO's are paid worldwide and how Company Shares can be a larger source of income than their multi million dollar salaries. I look at the conflict of interest that often comes with awarding incentives and bonuses.

I chat with Dave Ahern from Investing for Beginners Podcast about Novo Nordisk and the meteoric rise of their share price and how Ozempic and Wegovy have driven that.

Documents Links that are mentioned in the Podcast:

Ozempic Dosage Trial

The SUSTAIN 4 Clinical Trial

2016 Novo Nordisk Annual Report

2023 Renumeration Report of Novo Nordisk

Time Article on Lars Jorgensen

Financial Times Article on Lars Jorgensen

Harvard Business Review CEO of the year article on Lars Sorensen

Contact

[email protected]

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECTS of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. We encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.

To see the fully formed picture of the new weight loss drugs I've had to dig deep. Years of research and interviews with scientists and health professionals. This is no junior jigsaw puzzle - it's a pretty tricky one - so get on board!

This week we follow the twists... and turn over three major puzzle pieces of the hidden picture to reveal the truth behind the new weight loss drugs. We look at Government Regulators, Drug Companies and the Worldwide Obesity Epidemic.

We ask the Question: Is this potentially the Perfect Storm - Because we have never had these three events coincide before.

Is it a small rain shower or a Stage 5 hurricane? - it's anyone's guess.

Plus we take a look at what to expect from the Podcast.

Episodes will drop weekly approximately.

Contact

[email protected]

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECTS of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of advice on if these drugs are suitable for Diabetics. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. We encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.

I want to tell you how this whole whole thing started. I was in the process of writing my fifth book, researching and writing about the new weight loss drugs - in particular Ozempic and Wegovy. I was reading clinical trials and medical reports. but the further I looked the more there was to see and what I found often wasn't pretty.

Plus I couldn't believe people were not even talking about these issues...like at all. I realised pretty quickly that no one knew the full story.

I reached out to scientists, Government regulators worldwide and medical professionals to confirm what I'd found. I applied for documents through freedom of information.

We're going to start at the beginning of my journey and tell you exactly what I've found and what I think it means. We're going to attach all of the documents so you can have a look too. I'm also issuing an open invitation to the manufacturer Novo Nordisk to answer my many emails which as yet have received no answer.

If you're thinking of taking these new weight loss drugs or possibly you already are you might want to have a listen. I'm going to drop episodes weekly until all of the jigsaw pieces fall into place for you, and you too can see the totally shocking picture.

Follow our podcast called Investigating Ozempic which will be COMING SOON.

We look forward to you joining us. SUBSCRIBE to follow.

Music from #Uppbeat

https://uppbeat.io/t/philip-anderson/achievement

License code: J2HHAZ0N0WPZMQKP

DISCLAIMER:

The Investigating Ozempic and Wegovy Podcast (Investigating Ozempic) is not an alternative for good medical advice. We are not medical professionals and encourage you to talk to your own medical professional for your own healthcare needs. The podcast is an expression of honest opinion by the hosts and is not intended to defame any parties. There has been every endeavour to obtain true and authentic information in the formation of those opinions. Fair Usage Copyright has been applied.